Literature DB >> 1629706

The role of CD8+T cells in the acute and chronic phases of Theiler's murine encephalomyelitis virus-induced disease in mice.

P Borrow1, P Tonks, C J Welsh, A A Nash.   

Abstract

The technique of in vivo depletion with T cell subset-specific monoclonal antibodies was used to study the involvement of CD8+T cells in protection/pathogenesis during the acute and chronic demyelinating phases of Theiler's murine encephalomyelitis virus (TMEV)-induced disease. Mice rendered CD8-deficient prior to infection with TMEV were less efficient at clearing virus from the central nervous system compared to intact animals and also suffered demyelinating disease of earlier onset and increased severity. This indicates that CD8+ cells have a protective role in virus clearance at early times post-infection, and may also be involved in downregulating the severity of the chronic demyelinating disease. How CD8+ T cells function to produce these effects is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1629706     DOI: 10.1099/0022-1317-73-7-1861

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  32 in total

1.  Differences in avidity and epitope recognition of CD8(+) T cells infiltrating the central nervous systems of SJL/J mice infected with BeAn and DA strains of Theiler's murine encephalomyelitis virus.

Authors:  Bong-Su Kang; Michael A Lyman; Byung S Kim
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Interleukin-6 as a mechanism for the adverse effects of social stress on acute Theiler's virus infection.

Authors:  Mary W Meagher; Robin R Johnson; Erin E Young; Elisabeth G Vichaya; Shannon Lunt; Elizabeth A Hardin; Marilyn A Connor; C Jane R Welsh
Journal:  Brain Behav Immun       Date:  2007-06-25       Impact factor: 7.217

3.  H-2D(b-/-) mice are susceptible to persistent infection by Theiler's virus.

Authors:  A Azoulay-Cayla; S Dethlefs; B Pérarnau; E L Larsson-Sciard; F A Lemonnier; M Brahic; J F Bureau
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  The immune system preferentially clears Theiler's virus from the gray matter of the central nervous system.

Authors:  M K Njenga; K Asakura; S F Hunter; P Wettstein; L R Pease; M Rodriguez
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  A critical role for virus-specific CD8(+) CTLs in protection from Theiler's virus-induced demyelination in disease-susceptible SJL mice.

Authors:  Meghann Teague Getts; Maureen H Richards; Stephen D Miller
Journal:  Virology       Date:  2010-04-08       Impact factor: 3.616

6.  Chronic social stress impairs virus specific adaptive immunity during acute Theiler's virus infection.

Authors:  Erin E Young; Elisabeth G Vichaya; Nicole M Reusser; Jennifer L Cook; Andrew J Steelman; C Jane R Welsh; Mary W Meagher
Journal:  J Neuroimmunol       Date:  2012-09-27       Impact factor: 3.478

Review 7.  Neuroimmune interactions in a model of multiple sclerosis.

Authors:  C Jane Welsh; Andrew J Steelman; Wentao Mi; Colin R Young; Ralph Storts; Thomas H Welsh; Mary W Meagher
Journal:  Ann N Y Acad Sci       Date:  2009-02       Impact factor: 5.691

8.  Identification of a major T-cell epitope within VP3 amino acid residues 24 to 37 of Theiler's virus in demyelination-susceptible SJL/J mice.

Authors:  R L Yauch; K Kerekes; K Saujani; B S Kim
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Pro-inflammatory functions of astrocytes correlate with viral clearance and strain-dependent protection from TMEV-induced demyelinating disease.

Authors:  Pamela A Carpentier; Meghann Teague Getts; Stephen D Miller
Journal:  Virology       Date:  2008-03-04       Impact factor: 3.616

10.  Anticapsid immunity level, not viral persistence level, correlates with the progression of Theiler's virus-induced demyelinating disease in viral P1-transgenic mice.

Authors:  Jinjong Myoung; Young Yil Bahk; Hyun Seok Kang; Mauro C Dal Canto; Byung S Kim
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.